Medytox Temporarily Suspends Manufacturing and Sales of Meditoxin and Coretox Stocks Worth 104.9 Billion KRW

[Asia Economy Reporter Geum Bo-ryeong] Medytox announced on the 20th that it will temporarily suspend the manufacturing and sales of Meditoxin Injection (Clostridium botulinum toxin type A) and Coretox Injection (Clostridium botulinum toxin type A (150kDa)).

The amount affected by the suspension is approximately 104.9 billion KRW, which accounts for 50.93% of last year's consolidated sales.

Medytox stated, "We received a notification from the Daejeon Regional Food and Drug Administration ordering the temporary suspension of manufacturing and sales for the pharmaceuticals confirmed to have been sold without national batch approval, pursuant to Article 71 of the Pharmaceutical Affairs Act." They added, "We plan to file for a suspension of execution and a lawsuit to cancel the order at the Daejeon District Court."